Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
Author
Cruz-Bermúdez, Alberto; Laza-Briviesca, Raquel; Vicente-Blanco, Ramiro J.; García-Grande, Aránzazu; Coronado, Maria José; Laine Menéndez, Sara; Palacios-Zambrano, Sara; Moreno-Villa, M. Rocío; Martín Ruiz-Valdepeñas, Asunción; Lendinez, Cristina; Romero, Atocha; Franco, Fernando; Calvo de Juan, Virginia; Alfaro, Cristina; Martín Acosta, Paloma; Salas, Clara; Garcia, José Miguel; Provencio Pulla, MarianoEntity
UAM. Departamento de Anatomía Patológica; UAM. Departamento de Bioquímica; UAM. Departamento de Medicina; Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM)Publisher
Elsevier Inc.Date
2019-05-14Citation
10.1016/j.freeradbiomed.2019.03.009
Free Radical Biology and Medicine 135 (2019): 167-181
ISSN
0891-5849 (print); 1873-4596 (online)DOI
10.1016/j.freeradbiomed.2019.03.009Funded by
Work in the authors’ laboratories is supported by ‘‘Instituto de Salud Carlos III’’ PI13/01806 and PIE14/0064 to M.P. A.C-B, received a Spanish Lung Cancer Group fellowship. R.L-B, is supported by Comunidad Autónoma de Madrid “Garantía juvenil” contractProject
Gobierno de España. PI13/01806; Gobierno de España. PIE14/0064Editor's Version
https://doi.org/10.1016/j.freeradbiomed.2019.03.009Subjects
Chemoresistance; Chemotherapy; Metabolism; Metformin; NSCLC; MedicinaRights
© 2019 The AuthorsEsta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.
Abstract
Background: Platinum-based chemotherapy remains the standard of care for most lung cancer cases. However chemoresistance is often developed during the treatment, limiting clinical utility of this drug. Recently, the ability of tumor cells to adapt their metabolism has been associated to resistance to therapies. In this study, we first described the metabolic reprogramming of Non-Small Cell Lung Cancer (NSCLC) in response to cisplatin treatment. Methods: Cisplatin-resistant versions of the A549, H1299, and H460 cell lines were generated by continuous drug exposure. The long-term metabolic changes, as well as, the early response to cisplatin treatment were analyzed in both, parental and cisplatin-resistant cell lines. In addition, four Patient-derived xenograft models treated with cisplatin along with paired pre- and post-treatment biopsies from patients were studied. Furthermore, metabolic targeting of these changes in cell lines was performed downregulating PGC-1α expression through siRNA or using OXPHOS inhibitors (metformin and rotenone). Results: Two out of three cisplatin-resistant cell lines showed a stable increase in mitochondrial function, PGC1-α and mitochondrial mass with reduced glycolisis, that did not affect the cell cycle. This phenomenon was confirmed in vivo. Post-treatment NSCLC tumors showed an increase in mitochondrial mass, PGC-1α and a decrease in the GAPDH/MT-CO1 ratio. In addition, we demonstrated how a ROS-mediated metabolism reprogramming, involving PGC-1α and increased mitochondrial mass, is induced during short-time cisplatin exposure. Moreover, we tested how cells with increased PGC-1a induced by ZLN005 treatment, showed reduced cisplatin-driven apoptosis. Remarkably, the long-term metabolic changes, as well as the metabolic reprogramming during short-time cisplatin exposure can be exploited as an Achilles’ heel of NSCLC cells, as demonstrated by the increased sensitivity to PGC-1α interference or OXPHOS inhibition using metformin or rotenone. Conclusion: These results describe a new cisplatin resistance mechanism in NSCLC based on a metabolic reprogramming that is therapeutically exploitable through PGC-1α downregulation or OXPHOS inhibitors.
Files in this item
Google Scholar:Cruz-Bermúdez, Alberto
-
Laza-Briviesca, Raquel
-
Vicente-Blanco, Ramiro J.
-
García-Grande, Aránzazu
-
Coronado, Maria José
-
Laine Menéndez, Sara
-
Palacios-Zambrano, Sara
-
Moreno-Villa, M. Rocío
-
Martín Ruiz-Valdepeñas, Asunción
-
Lendinez, Cristina
-
Romero, Atocha
-
Franco, Fernando
-
Calvo de Juan, Virginia
-
Alfaro, Cristina
-
Martín Acosta, Paloma
-
Salas, Clara
-
Garcia, José Miguel
-
Provencio Pulla, Mariano
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
Cruz-Bermúdez, Alberto; Laza-Briviesca, Raquel; Vicente-Blanco, Ramiro J.; García-Grande, Aránzazu; Coronado, Maria José; Laine Menéndez, Sara; Alfaro, Cristina; Sánchez, Juan Cristóbal; Franco, Fernando; Calvo de Juan, Virginia; Romero, Atocha; Martín-Acosta, Paloma; Salas, Clara; García, José Miguel; Provencio Pulla, Mariano
2018-11-01 -
Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients
Provencio Pulla, Mariano; Pérez-Callejo, David; Torrente, María; Martín, Paloma; Calvo de Juan, Virginia; Gutiérrez, Lourdes; Franco, Fernando; Coronado, María José; Cruz-Bermúdez, Juan Luis; Martín Ruiz-Valdepeñas, Asunción; Cruz-Bermúdez, Alberto; Sánchez-Beato, Margarita; Romero, Atocha; García-Grande, Aránzazu
2017-07-31 -
Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment
Provencio Pulla, Mariano; Torrente, María; Calvo de Juan, Virginia; Gutiérrez, Lourdes; Pérez-Callejo, David; Pérez-Barrios, Clara; Barquín, Miguel; Royuela Vicente, Ana; Rodríguez-Alfonso, Begoña; Sotelo, Miguel; Cruz-Bermúdez, Juan Luis; Mendez, Miriam; Cruz-Bermúdez, Alberto; Romero, Atocha
2017-08-07